A Randomized Open-Label Phase 3 Trial of Tisotumab Vedotin vs Investigator s Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Cervical Cancer
  • Age: Between 18 - 100 Years
  • Gender: Female
  • Other Inclusion Criteria:
    1. 1. Has recurrent or metastatic cervical cancer with squamous cell, adenocarcinoma, or adenosquamous histology.
    2. 2. Has life expectancy of at least 3 months.
    3. 3. Has a negative serum pregnancy test for participants of reproductive potential.

You may not be eligible for this study if the following are true:

    1. 1. Has clinically significant bleeding issues or risks.
    2. 2. Has cardiovascular issues or risks.
    3. 3. Central nervous system (CNS): any history of intracerebral arteriovenous malformation, cerebral aneurysm, or stroke (transient ischemic attack >1 month prior to screening is allowed).



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.